Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT06039384 |
TitleINCB099280 联合 Adagrasib 治疗携带 KRASG12C 突变的晚期实体瘤成人研究 | 阶段
第 1 阶段
|
Date Added 2023-09-15 |
地点
California, United States
Colorado, United States Michigan, United States Texas, United States Virginia, United States 意大利 西班牙 英国 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Adagrasib, INCB099280 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05652894 |
TitleA Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer | 阶段
第三阶段
|
Date Added 2022-12-15 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
尚未招聘
|
药物
HX008, Investigator's Choice Chemotherapy |
标签
MSI-H/ MMRd
|
| NCT ID NCT03970382 |
TitleA Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | 阶段
第 1 阶段
|
Date Added 2019-05-31 |
地点
California, United States
Illinois, United States New York, United States Tennessee, United States Washington, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
暂停
|
药物
IL-2, NeoTCR-P1 adoptive cell therapy, Nivolumab |
标签
MSS/ MMRp
|
| NCT ID NCT03013218 |
TitleA Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) | 阶段
第 1 阶段
|
Date Added 2017-01-06 |
地点
Colorado, United States
Connecticut, United States Massachusetts, United States Michigan, United States Washington, United States 大韩民国 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
5-FU + Cisplatin, Evorpacept (ALX148), Pembrolizumab, Ramucirumab + Paclitaxel, Rituximab, Trastuzumab |
标签
MSS/ MMRp
|
| NCT ID NCT04607421 |
TitleA Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER) | 阶段
第三阶段
|
Date Added 2020-10-29 |
地点
Arizona, United States
California, United States Florida, United States Illinois, United States Louisiana, United States Minnesota, United States Missouri, United States Nebraska, United States New Jersey, United States New York, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States 阿根廷 澳大利亚 比利时 巴西 Bulgaria 加拿大 中国 Czechia 丹麦 Finland 德国 India 意大利 日本 大韩民国 墨西哥 荷兰 新西兰 挪威 波兰 Russian Federation Slovakia 南非 西班牙 瑞典 台湾 Ukraine 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
5-FU, Bevacizumab, capecitabine, cetuximab, encorafenib, Irinotecan, Leucovorin, oxaliplatin |
标签
MSS/ MMRp
|
| NCT ID NCT05217446 |
TitleA Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer ( SEAMARK ) | 阶段
第二阶段
|
Date Added 2022-02-01 |
地点
Arizona, United States
California, United States Florida, United States Illinois, United States Minnesota, United States New York, United States Tennessee, United States Texas, United States 澳大利亚 比利时 加拿大 Czechia 丹麦 法国 德国 意大利 荷兰 挪威 波兰 Slovakia 西班牙 瑞典 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
encorafenib, Braftovi, Erbitux, Keytruda |
标签
MSI-H/ MMRd
|
| NCT ID NCT05726864 |
TitleA Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors | 阶段
Phase 1, Phase 2
|
Date Added 2023-02-14 |
地点
Arizona, United States
California, United States Colorado, United States Florida, United States Georgia, United States Iowa, United States Louisiana, United States Massachusetts, United States Michigan, United States Minnesota, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Wisconsin, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
ELI-002 7P |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04104776 |
TitleCPI-0209 对晚期实体瘤和淋巴瘤患者的研究 | 阶段
第 1 阶段
|
Date Added 2019-09-26 |
地点
Georgia, United States
Illinois, United States Maryland, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Texas, United States Virginia, United States Washington, United States 法国 意大利 大韩民国 波兰 西班牙 英国 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
CPI-0209, CPI-0209 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05759728 |
Title针对转移性结直肠癌受试者的 CNA3103（LGR5 靶向自体 CAR-T 细胞）研究 | 阶段
第 1 阶段
|
Date Added 2023-03-08 |
地点
澳大利亚
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03783403 |
TitleA Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers | 阶段
第 1 阶段
|
Date Added 2018-12-21 |
地点
Alabama, United States
Arizona, United States California, United States Colorado, United States Missouri, United States New York, United States North Carolina, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States 澳大利亚 加拿大 法国 意大利 大韩民国 西班牙 英国 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
CC-95251, cetuximab, Rituximab |
标签
MSS/ MMRp
|
